{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "CNTA",
  "name": "Centessa Pharmaceuticals plc",
  "url": "https://frontierpicks.com/dossiers/CNTA/",
  "json_url": "https://frontierpicks.com/dossiers/CNTA.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Closed cash-plus-CVR takeout; nothing trades. Lilly's scheme ($38.00 cash plus a non-transferable CVR of up to $9.00) went effective 2026-06-24, Form 15-12G dated 2026-07-06. New since the last note: ClinicalTrials.gov lists a Phase 2/Phase 3 cleminorexton study (NCT07598708) recruiting since 2026-05-29 versus Lilly's Phase 2a language on 2026-08-05 — CVR-relevant, unexpressible in this symbol.",
  "invalidation_trigger": "",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "m-and-a-special-situations",
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "No US-listed equity remains: the ADSs delisted from Nasdaq 2026-06-24 and the Form 15-12G deregistration filing is dated 2026-07-06.",
    "The up-to-$9.00 CVR is non-transferable and went to scheme record holders; it cannot be bought, sold or hedged after close.",
    "Any CNTA price a data vendor still renders is the 2026-06-23 final session print of $40.50, not a live quote; it screens 0.0% from its 52-week high.",
    "Clinical trial records still list Centessa Pharmaceuticals (UK) Limited as sponsor, now a Lilly subsidiary, so registry sponsor names lag the ownership change.",
    "Lead asset renamed: ORX750 is now cleminorexton; ORX142 and ORX489 also sit inside the merger proxy's candidate perimeter.",
    "Orexin-class read-through flows to Takeda (ORZEYFUL), Alkermes (alixorexton) and Lilly (cleminorexton), never back to this symbol."
  ],
  "body_markdown": "## Current Thesis\nThe special situation closed by consummation and the listed instrument no longer exists; what remains is a contingent-value question that cannot be expressed in this symbol. Eli Lilly's UK scheme of arrangement — **$38.00 cash per share plus one non-transferable contingent value right of up to $9.00** — became effective 2026-06-24 through LDH XV Corporation after High Court sanction on 2026-06-22 (CNTA Form 8-K, 2026-06-24). The final Nasdaq ADS session was 2026-06-23; the Form 15-12G deregistering the ADSs is dated 2026-07-06.\n\nOne thing has advanced since the prior note. ClinicalTrials.gov carries **NCT07598708**, \"A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence,\" listed as **Phase 2/Phase 3, Recruiting, start date 2026-05-29, primary completion 2027-09-30**, sponsored by Centessa Pharmaceuticals (UK) Limited (registry record retrieved 2026-08-23). That sits alongside Lilly's own second-quarter release of 2026-08-05, which still described cleminorexton (formerly ORX750) as having shown a potential best-in-class profile in **Phase 2a** studies. The registry field is sponsor-entered and revisable, so it is a dated indication of program stage, not a company statement of registrational start. That distinction is the entire live question for CVR milestone timing — and the CVR pays scheme record holders.\n\n## Bull Case\n- **Consideration cleared with no re-cut.** Sanction 2026-06-22, effective 2026-06-24, $38.00 cash fixed (Form 8-K, 2026-06-24). Announcement day 2026-03-31 produced a ~45% single-session move on headline value around $7.8B and roughly a 40% premium (Benzinga, 2026-03-31 / 2026-04-01).\n- **Registry stage now runs ahead of the press language.** NCT07598708 is listed Phase 2/Phase 3 and recruiting since 2026-05-29, with primary completion 2027-09-30 — the first dated public marker of work beyond a pure 2a design (ClinicalTrials.gov, retrieved 2026-08-23).\n- **The predecessor study is still generating data.** NCT06752668 (\"A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia\"), Phase 2, start 2024-12-23, remains listed as recruiting with a December 2026 primary completion.\n- **The asset survived its first reporting cycle inside the acquirer.** Lilly's 2026-08-05 release names Centessa under completed Q2 business development and names cleminorexton, rather than folding it into an unnamed neuroscience line. Lilly reported Q2 revenue of $23.0B, +48% year over year, and raised FY2026 guidance to $85.0–87.0B in the same release.\n- **The CVR perimeter is wider than one molecule.** The merger proxy names cleminorexton, ORX142 and ORX489 (DEFM14A filed 2026-05-07; PREM14A 2026-04-17).\n- **The mechanism has cleared a US review.** FDA approved Takeda's ORZEYFUL (oveporexton), an oral OX2R agonist, for NT1 on 2026-08-05 on two randomized double-blind placebo-controlled Phase 3 trials enrolling 273 adults.\n\n## Bear Case\n- **There is no security to own.** Delisted 2026-06-24; Form 15-12G dated 2026-07-06. Any CNTA quote a vendor still renders is the 2026-06-23 print on a dormant feed.\n- **The CVR is non-transferable.** It went to scheme record holders under the CVR Agreement (proxy Annex B) and cannot be bought, sold or hedged. A favourable cleminorexton outcome produces no move in this symbol under any scenario.\n- **Milestone terms are not observable at the level that matters.** The aggregate is capped at $9.00 per share; the individual triggers and dates are not disclosed in a form that lets an outsider mark progress against them.\n- **The clock is long.** Primary completion on NCT07598708 is 2027-09-30. Even on the registry's own dates, resolution of the registrational question sits well past 2026.\n- **The follower problem hardened on 2026-08-05.** ORZEYFUL is approved in NT1. Alkermes announced initiation of the Phase 3 Brilliance program on 2026-04-01 — three 12-week randomized, double-blind, placebo-controlled studies (302 and 304 in NT1, 303 in NT2) of alixorexton.\n- **Sell-side marks are frozen artefacts.** Needham. Nothing has been revised since 2026-04-20 because there is nothing to rate.\n\n## Setup & Price Structure\nThe narrative is **dead** — structure broken by delisting, dated by the last tradable session on 2026-06-23, the 2026-06-24 effectiveness of the scheme, and the 2026-07-06 Form 15-12G. The orexin narrative itself is alive and accelerating; it simply no longer has this ticker as a vehicle.\n\nThe tape is frozen at one session. The 2026-06-23 adjusted close of $40.50 is also the 52-week high — the name screens 0.0% below it — with RSI(14) at 71.1 and a three-month price change of +45.2%, all fixed at that print. No session has occurred since; the vendor timestamp does not advance.\n\nCrowding and positioning observables, stated as observables: a momentum screen run today returns a name at its 52-week high with a 71-handle RSI and zero subsequent volume, which is a data artefact of the halt rather than participation. The pre-vote register into the 2026-06-12 scheme meeting was institutional-heavy — Samlyn, Bain and Perceptive appear in the pre-close 13F record — and the June tape was deal arbitrage rather than retail-squeeze mechanics. There is no upcoming earnings date, no analyst revision flow since 2026-04-20, and no possibility of insider Form 4 activity: Section 16 duties ended with deregistration. Issuance into strength is likewise impossible.\n\n## Catalyst Calendar (next 30 days)\n- **2026-08-23 → 2026-09-22:** no dated company event falls in the window. No earnings date, no filing deadline, no listing on which a print can occur.\n- **~2026-10-04 (est.):** termination of ADS registration on the standard 90-day path from the 2026-07-06 Form 15-12G — the last public-disclosure channel on the entity closes.\n- **~2026-10-29 (est.):** Lilly third-quarter 2026 results and pipeline update — the first scheduled disclosure where a cleminorexton registrational start, or a demotion, would surface.\n- **~December 2026 (est., per registry):** primary completion listed for NCT06752668, the Phase 2 ORX750 study.\n- **2027-09-30 (registry-listed):** primary completion for NCT07598708, the Phase 2/Phase 3 cleminorexton study.\n\n## What Would Change Our Mind\nThe structural facts, not the price, are what would have to move. Two conditions would reopen this symbol as a market object: a relisting of an entity that has already filed to stop Exchange Act reporting, or a change to the CVR's non-transferability creating a tradable claim. Neither has a filed path as of 2026-08-23, and the 90-day deregistration clock running to ~2026-10-04 points the other way.\n\nOn the CVR itself, the read changes on: NCT07598708 flipping from Recruiting to Suspended, Withdrawn or Terminated, or its phase field being revised down; cleminorexton being absent from or demoted in Lilly's Q3 pipeline table at the ~2026-10-29 release; or, in the other direction, an explicit Lilly statement of a registrational start, which would be the first company-sourced confirmation that the registry entry reflects a Phase 3 commitment.\n\nFor grading purposes, the price condition that would break a long thesis here is a daily close below $38.00 — the scheme's cash consideration — and it cannot print, because no session has occurred since 2026-06-23 and none will.\n\n## Correlation Notes\n- Read-through from cleminorexton now expresses in **LLY** (acquirer; at $23.0B of Q2 revenue, the asset is immaterial to the parent's price), **Takeda** (ORZEYFUL approved 2026-08-05, the NT1 first-mover) and **ALKS** (alixorexton, Brilliance Phase 3 initiated per the 2026-04-01 announcement). Orexin-class sentiment moves those, never this symbol.\n- Takeout-beta correlation ended on 2026-06-23. On the 2026-03-31 announcement tape, CNTA moved alongside Apellis, which was +136.4% on a Biogen buyout at $41/share — a same-session biotech M&A cluster. CNTA no longer contributes covariance to anything; the series is a constant.\n- For anyone running a screen or backtest across this window, the frozen $40.50 print will behave as a live near-high observation and will bias any momentum or breadth statistic that includes it.",
  "first_seen": "2026-04-19",
  "last_analyzed": "2026-08-23T11:38:38+00:00",
  "last_synthesized": "2026-08-23",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}